SYNTHON HISPANIA SL
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SYNTHON HISPANIA SL
Live alerts from global media, monitored by Business Radar
2012-02-08 (deaandeelhouder.nl)
Pharmaceutical company Synthon wants to go public
Synthon wants to make the transition from generic medicines to self-developed medicines.
Read more
(quotenet.nl)
Jacques Lemmens is considering the Synthon IPO
The fact that things are going well in the medical pills and drinks sector is an easy statement to swallow. After all, unless miracles really exist, people will always get sick. The Nijmegen Synthon once again achieved a turnover of millions last year by developing and marketing unbranded medicines. However, to continue to grow the company needs much more cash. So much that a – partial – IPO is a serious option.
Read more